scispace - formally typeset
C

Charles F. von Gunten

Researcher at OhioHealth

Publications -  156
Citations -  4020

Charles F. von Gunten is an academic researcher from OhioHealth. The author has contributed to research in topics: Palliative care & End-of-life care. The author has an hindex of 30, co-authored 145 publications receiving 3790 citations. Previous affiliations of Charles F. von Gunten include Riverside Methodist Hospital & University of California, San Diego.

Papers
More filters
Journal ArticleDOI

Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness a randomized clinical trial

TL;DR: It is suggested that stopping statin medication therapy is safe and may be associated with benefits including improved QOL, use of fewer nonstatin medications, and a corresponding reduction in medication costs.
Journal ArticleDOI

Palliative Cancer Care a Decade Later: Accomplishments, the Need, Next Steps—From the American Society of Clinical Oncology

TL;DR: The need for palliative cancer care is greater than ever notwithstanding the strides made over the last decade, and further efforts are needed to realize the integration of palliatives care in the model and vision of comprehensive cancer care by 2020.
Journal ArticleDOI

Ensuring Competency in End-of-Life Care Communication and Relational Skills

TL;DR: A 7-step approach for physicians for structuring communication regarding care at the end of life is presented, which can be used in situations such as breaking bad news, setting treatment goals, advance care planning, withholding or withdrawing therapy, making decisions in sudden life-threatening illness, and resolving conflict around medical futility.
Journal ArticleDOI

Secondary and tertiary palliative care in US hospitals.

Charles F. von Gunten
- 20 Feb 2002 - 
TL;DR: The case of Reverend J, a man with advanced cancer admitted to an acute palliative care unit in a teaching hospital, illustrates the use of secondary and tertiary clinical palliatives care services in hospitals and health care systems.
Journal ArticleDOI

Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study.

TL;DR: In conclusion, methylnaltrexone relieved opioid-induced constipation at doses >or=5mg in patients with advanced illness, and did not reduce analgesia or cause opioid withdrawal symptoms.